Photon Fund
Photon Fund is a venture capital firm based in Shenzhen, China, with additional offices in Beijing and Silicon Valley. Established in 2015, the firm specializes in early-stage investments across various sectors, including technology, innovation, media, telecommunications, advanced manufacturing, and new materials. The core team possesses over 20 years of experience in equity investment, focusing on technology, media, and telecommunications, as well as high-end manufacturing. Photon Fund emphasizes a research-driven approach, prioritizing independent judgment and value creation for its portfolio companies. The firm's investment philosophy aims to foster scientific and technological advancement, playing a significant role in promoting innovation within China and on a global scale.
Bichen Pharmaceutical is a small-molecule tumor-targeted drug developer for the treatment of various malignant tumors and brain metastases.
Amplicore is a develop injectable therapeutics for degenerative musculoskeletal disorders to serve unmet medical needs. They take a regenerative approach to joint osteoarthritis, cartilage damage, degenerative disc disease, and acute meniscus tears.
Newomics is an early stage biotechnology company that commercializes innovative and integrative platforms and solutions for personalized healthcare. Its proprietary technology is based on silicon-microfluidic-chip for liquid chromatography-mass spectrometry (LC-MS) and offers unprecedented robustness, sensitivity, specificity, and throughput for analyzing molecules from minute amounts of biospecimens such as blood and urine.
Cardea is developing a new generation of (bio)technology infrastructure based on proprietary biology-gated transistors. Cardean transistors leverage biocompatible graphene instead of silicon and replace optical signal observations with direct electrical molecular signal analysis. With Cardean transistors, the company and its Innovation Partners can generate streaming multi-omics data to measure real-time biological signals. Cardea is now manufacturing chips at scale and partners have started to significantly expand the amount, type, and quality of biological data they capture by building products that Conduct Biolog.
Nelumbo is commercializing a new platform of structural materials. The company’s current focus is on developing improved heat exchangers for the HVAC market. Our ability to improve energy performance and minimize corrosion in a single platform unlocks mass market opportunity with potential for significant carbon emission and energy use reductions worldwide.
CASPR Biotech develops a CRISPR-based platform for molecular detection.
Valitor, Inc. has developed novel methods of modifying therapeutic proteins to achieve substantial control over their pharmacokinetics, target specificity and bioactivity. Their technology platform can be broadly applied to improve the pharmacological properties of many protein drugs that are currently approved or under development. They currently have three development pipelines in the fields of dermatology, ophthalmology, and orthopedics that highlight the capabilities of their novel drug products.
Newomics is an early stage biotechnology company that commercializes innovative and integrative platforms and solutions for personalized healthcare. Its proprietary technology is based on silicon-microfluidic-chip for liquid chromatography-mass spectrometry (LC-MS) and offers unprecedented robustness, sensitivity, specificity, and throughput for analyzing molecules from minute amounts of biospecimens such as blood and urine.
Nelumbo is commercializing a new platform of structural materials. The company’s current focus is on developing improved heat exchangers for the HVAC market. Our ability to improve energy performance and minimize corrosion in a single platform unlocks mass market opportunity with potential for significant carbon emission and energy use reductions worldwide.
CARsgen is a leading clinical-stage immunotherapy company focused on the development of new chimeric antigen receptor T (CAR-T) cell therapeutics for liver, lung, stomach and brain cancers. The company has partnership with Shanghai Cancer Institute and Shanghai Renji Hospital. The company is leading the first tier of CAR-T development, by completing World’s first hepatocellular carcinoma (HCC) and China’s exclusive glioblastoma multiforme (GBM) dose ascending injection tests. Funded by leading venture capital firm BVCF, CARsgen is well-positioned to bring a novel cancer therapeutics to the market in China and worldwide.
Hongliyu Cinema is a Chinese rural cinema operator. It focuses on film and television production and advertising operation services, and professional support in China.
Techtotop has four generations of satellite navigation and positioning chips that have been released by the company. Vehicle navigation, vehicle and personal monitoring, smart wear, emerging IoT, smart grid, radio and television, time synchronization, sub-meter precision, and other fields make extensive use of the products.
Yuedan is a personal services trading platform. They serve the people and commercial businesses. It provides a platform for time selling and skill trading, dedicated to helping more people who have time or skills to cash in. They offer to find nearby service providers.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.